Kaitlin Batley
Neurology with Special Qualifications in Child Neurology · Dallas, TXNPI 1124412028
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Sarepta Therapeutics, Inc. at 24.4% of the total. 2025 is the largest year on record at $33,116, 4.2 times the $7,856 reported in 2022. Among neurology with special qualifications in child neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $418.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$18K
- Novartis$12K
- Pfizer$9K
- Biogen$8K
- ITF Therapeutics LLC$6K
- PTC Therapeutics, Inc.$6K
- plus $15K from 15 others
Across 63 payments — averaging $7397.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$103K
- Sarepta Therapeutics, Inc.$92K
- NS Pharma, Inc.$80K
- UCB SA$80K
- Amicus Therapeutics, Inc.$62K
- Catalyst Pharmaceuticals, Inc.$48K
What the payments were for
- Consulting fees$43,99560%
- Speaking & faculty fees$15,35721%
- Travel & lodging$7,55810%
- Food & beverage$6,7069%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 29 | $17,940 |
| Novartis | 10 | $11,629 |
| Pfizer | 8 | $8,668 |
| Biogen | 18 | $8,428 |
| ITF Therapeutics LLC | 19 | $5,828 |
| PTC Therapeutics, Inc. | 6 | $5,707 |
| Janssen Scientific Affairs, LLC | 10 | $5,015 |
| Catalyst Pharmaceuticals, Inc. | 7 | $4,405 |
| UCB, Inc. | 13 | $3,580 |
| Genentech, Inc. | 4 | $769 |
| Genentech USA, Inc. | 20 | $702 |
| Argenx US, Inc. | 3 | $362 |
| NS Pharma, Inc. | 14 | $236 |
| Sanofi | 4 | $97 |
| Jazz Pharmaceuticals Inc. | 2 | $71 |
| Upsher-smith Laboratories LLC | 2 | $66 |
| Acadia Pharmaceuticals Inc | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| Immedica Pharma US, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,645 in reported general payments places this provider in the 95th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Other neurology with special qualifications in child neurology in Dallas
- Roy EltermanDallas$5.9M
- Raphael SchiffmannDallas$88K
- Mauricio Delgado-AyalaDallas$75K
- Daniel GossettDallas$36K
- Zurisadai Gonzalez CastilloDallas$30K
- Steven SparaganaDallas$7K
- Berge MinassianDallas$5K
- Charuta JoshiDallas$4K
- David OwenDallas$4K
- Deepa SirsiDallas$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.